Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01515098
Other study ID # 11-2075
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2012
Est. completion date March 2015

Study information

Verified date March 2022
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Purpose: The purpose of this study is to examine the effect of blueberry consumption on cognitive decline and body composition in humans. Hypothesis 1: Adults with mild cognitive decline who consume blueberries will experience an improvement in cognitive abilities as measured by a standardized battery of tests, relative to those who consume a placebo. Hypothesis 2: Adults with mild cognitive decline who consume blueberries will evidence an increase in processing speed and an improvement in memory abilities as measured in an electrophysiological paradigm and compared to those who consume a placebo. Hypothesis 3: Daily intake of 35 g freeze-dried blueberries will improve body composition (fat mass vs. lean mass). Hypothesis 4: Daily intake of 35 g freeze-dried blueberries will decrease oxidative stress and inflammatory markers.


Recruitment information / eligibility

Status Completed
Enrollment 123
Est. completion date March 2015
Est. primary completion date March 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years to 79 Years
Eligibility Inclusion Criteria: - Men and women age 65 and older - BMI between 18.5 and 34.5 - Close individual to report memory decline Exclusion Criteria: - History of central nervous system or psychiatric disorders - Dementia or Alzheimer's diagnosis - Diabetes - Smoking >20 cigarettes/day - Gastrointestinal/digestive disorders - Uncontrolled chronic disease

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Freeze-dried blueberries
Wild blueberries, freeze-dried and pulverized
Dextrose Placebo
Placebo developed to closely match blueberry powder.

Locations

Country Name City State
United States Nutrition Research Institute Kannapolis North Carolina

Sponsors (1)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in cognitive test performance Measured by CANTAB Baseline, 180 days
Primary Change in brain activity (N200, P300) related to cognitive abilities as measured by event-related potentials (ERP) Recognition memory, speed of processing, and memory consolidation as measured by the electrophysiological technique known as event-related potentials (ERP) Baseline, 180 days
Secondary Change in body mass distribution DXA scans to measure body composition at baseline and outcome will be compared for differences Baseline, 180 days
Secondary Change in oxidative stress and inflammatory markers as measured in blood and urine Oxidative stress and inflammatory markers will be measured in blood and compared between baseline and outcome. Baseline, 180 days